Replimune's Oncolytic Virus Achieves 47.8% Three-Year Survival in Checkpoint-Resistant Melanoma as Company Lines Up Third FDA Submission
IGNYTE trial data show 83.5% of responders alive at three years; Replimune plans third BLA resubmission after two FDA rejections.
5 min read5 sources